CBD Reduced Cue-Triggered Heroin Craving in a Small 2019 Trial
For people recovering from heroin use, cravings can return suddenly when they encounter reminders of past drug use—such as particular places, objects, or emotional states. Those cue-triggered reactions can make recovery more difficult, even after the physical symptoms of withdrawal have eased.
A 2019 clinical trial explored whether cannabidiol (CBD), a non-intoxicating compound found in cannabis, might help reduce that response. The study published in the American Journal of Psychiatry found that CBD reduced cue-induced heroin craving and anxiety in a small group of abstinent adults with heroin use disorder. The findings are promising, but they do not show that CBD prevents relapse or treats opioid use disorder on its own.
What the study examined
Researchers randomly assigned 42 people with a history of heroin use disorder to receive a placebo, 400 milligrams of CBD, or 800 milligrams of CBD once daily for three days. Participants were abstinent when they entered the study. During laboratory sessions, they were exposed to drug-related cues and neutral cues while researchers measured craving, anxiety, heart rate, and salivary cortisol levels.
Compared with placebo, CBD reduced the craving and anxiety provoked by heroin-related cues. Some of these effects were still evident seven days after the final dose. The researchers also observed reductions in cue-related heart rate and cortisol, and they reported no serious adverse effects during the trial.
However, the trial was exploratory and small. It was designed to measure short-term responses to drug cues—not whether participants remained abstinent over months or years. The study therefore cannot establish that CBD prevents relapse, eliminates heroin cravings in everyday life, or is more effective than established treatments.
Why cue-triggered cravings matter
Heroin is an opioid that rapidly reaches the brain and activates receptors involved in reward, pain, breathing, and other vital functions. The drug can cause respiratory depression, coma, and death, particularly when its potency is unpredictable or when it is used with other substances. Today, illicitly manufactured fentanyl and other potent synthetic opioids are major drivers of overdose deaths in the United States, although heroin remains a serious risk.
Repeated opioid use can produce tolerance and physical dependence. When use stops, withdrawal may include insomnia, diarrhea, muscle aches, sweating, restlessness, anxiety, and intense cravings. Environmental reminders of drug use can activate learned associations and contribute to renewed drug-seeking behavior.
The 2019 CBD trial focused on this psychological and physiological response to drug-related cues. It did not suggest that CBD replaces medications that stabilize opioid use disorder or that it can safely manage withdrawal without medical supervision.
How established treatment differs from CBD
Evidence-based treatment for opioid use disorder generally combines medication with counseling, behavioral support, and other services tailored to the individual. The FDA identifies buprenorphine, methadone, and naltrexone as approved medications for opioid use disorder. These medications can reduce withdrawal, decrease cravings, block or reduce opioid effects, and lower the risk associated with continued illicit opioid use.
Lofexidine is different: it is approved to help reduce symptoms of opioid withdrawal, but it is not one of the FDA-approved maintenance medications for opioid use disorder. Counseling and behavioral therapies can also help people manage stress, recognize triggers, develop coping strategies, and remain engaged in treatment. MedlinePlus provides an overview of medication and behavioral treatment options.
CBD remains investigational
The study used a controlled oral CBD preparation, not a typical medical-cannabis product or an over-the-counter CBD oil. Product quality, concentration, and labeling can vary widely among commercial products. The FDA has approved CBD in the prescription drug Epidiolex for certain seizure disorders, but CBD has not been approved as a treatment for heroin use disorder or opioid use disorder.
CBD may also interact with other medications and can carry risks, including liver injury and excessive sedation in some circumstances. Anyone considering CBD while taking methadone, buprenorphine, naltrexone, or other medications should discuss it with a qualified health professional.
The 2019 trial provides evidence that CBD may temporarily reduce anxiety and craving triggered by heroin-related cues. It does not establish CBD as a stand-alone treatment, prove that it prevents relapse, or justify replacing proven medications. Larger and longer clinical trials are needed to determine whether CBD can safely improve recovery outcomes when used alongside established care.
